(1S,3Ar,6As)-Octahydrocyclopenta(C)Pyrrole-1-Carboxylic Acid Tert-Butyl Ester Oxalate

How Does the Oxalate Counterion Affect Fmoc Protection Yields at Multi-Kilogram Scale?

Conversion of (1S,3aR,6aS)-octahydrocyclopenta[c]pyrrole-1-carboxylic acid tert-butyl ester oxalate into its Fmoc-protected building block is the predominant entry point for solid-phase peptide synthesis (SPPS) applications. The hydrogenoxalate form depresses the free amine nucleophilicity sufficiently that direct acylation with Fmoc-OSu in polar aprotic solvents without pre-neutralisation results in prolonged induction periods and variable conversion profiles. Production campaigns at 50–200 kg routinely neutralise the oxalate salt with aqueous 10% sodium carbonate at 0–5 °C until pH 8.5–9.0 is achieved, liberating the tertiary butyl ester free base which is subsequently extracted into 2-methyltetrahydrofuran. DIPEA has been evaluated as an organic-phase base, but the resulting DIPEA oxalate tends to oil out and entrains product, reducing isolated yield to ≈72% compared with ≥88% for the aqueous carbonate work-up. The extracted free base is dried over magnesium sulfate and concentrated below 35 °C to avoid premature tert-butyl ester thermolysis. Fmoc-OSu (1.05–1.10 equivalents) is added as a solid or as a concentrated DMF solution while maintaining internal temperature below 5 °C. Reaction progress is monitored by reverse-phase HPLC (C18, 40–95% acetonitrile in 0.1% TFA over 20 min, UV 220 nm): the Fmoc-carbamate product elutes at Rt ≈13.7 min and residual free amine oxalate precursor is absent within 3 h under normal stirring. The post-reaction mixture is washed with 1 M HCl, saturated NaHCO₃, and brine sequentially; any traces of dibenzofulvene are adsorbed onto silica gel during a plug filtration step. Crystallisation from isopropyl ether/hexane (1:3 v/v) affords Fmoc-(1S,3aR,6aS)-octahydrocyclopenta[c]pyrrole-1-carboxylic acid tert-butyl ester as a white crystalline solid with typical DSC endotherm onset at 108–112 °C (heating rate 10 °C/min, nitrogen purge).

For regulated GMP intermediate supply under ICH Q7 Section 8.3 “Unit Operations,” critical process parameters include the aqueous-organic phase split time (centrifugal extractors are preferred over gravity settlers to limit epimerisation risk during hold-up) and the vacuum drying ramp rate. Residual solvents are controlled in accordance with ICH Q3C Option 2: 2-methyltetrahydrofuran ≤500 ppm, isopropyl ether ≤5000 ppm, hexane ≤290 ppm. The Fmoc intermediate is not a final isolated API starting material but is routinely released with assigned expiry of 24 months when stored in double LDPE liners inside fibre drums at 2–8 °C and protected from light. End-use integration into SPPS employs the Fmoc-protected bicyclic amino acid at 0.4–0.6 M in DMF, activated with HCTU (1.0 eq) and DIPEA (2.0 eq) relative to resin substitution. Double couplings of 45 min each are standard for secondary amines on 2-chlorotrityl chloride resin; incomplete incorporation is readily detected by residual bromophenol blue stain at Kaiser test. Incorporation yield, assessed by Fmoc cleavage spectrophotometry at 301 nm, typically exceeds 97%. Table 1 summarises a representative certificate of analysis for a Fmoc building block campaign.

Scale-up experience on 1600 L glass-lined reactors indicates that the main process risk is emulsion formation during the carbonate wash, which is broken by the addition of 5% w/v sodium chloride and gentle recirculation through a plate coalescer. Prolonged exposure of the tert-butyl ester to pH above 9.5 at ambient temperature triggers saponification, generating the corresponding free acid which co-elutes with the Fmoc product and necessitates preparative HPLC reprocessing. Specifying the oxalate salt rather than the free base for transport eliminates the need for cold-chain logistics and substantially decreases amine oxidation during transcontinental shipment; in-house accelerated stability studies at 40 °C/75% RH for 6 months showed ≤0.3% total impurities increase for the oxalate compared with 2.8% for the free amine under identical conditions.

Telaprevir P2 Fragment Manufacture: Integrated Supply Chain from Protected Ester to API Intermediate

The (1S,3aR,6aS)-octahydrocyclopenta[c]pyrrole-1-carboxylic acid tert-butyl ester oxalate serves as the penultimate protected P2 fragment in the registered process of several first-generation HCV NS3/4A protease inhibitors, most notably telaprevir. In the convergent route described in product patent family EP 1572105 B1, the oxalate is suspended in ethyl acetate and converted to the free base with aqueous potassium carbonate ( 1.25 molar equivalents relative to oxalic acid functionality) at 15–20 °C. The organic phase is azeotropically dried and concentrated, and the resulting viscous oil is directly telescoped into the peptide coupling step without further purification. Condensation with (S)-2-(tert-butoxycarbonylamino)-non-8-enoic acid—or its activated ester—is conducted in anhydrous tetrahydrofuran using HATU (1.05–1.15 eq) and a tertiary amine base. In pilot-plant campaigns, 2,6-lutidine (3.0 eq) has proven superior to DIPEA for minimising Cα-epimerisation of the aliphatic acid component; epimer content is maintained below 0.5% when internal temperature is strictly held between -10 and -5 °C during HATU pre-activation and the initial 30 min of coupling. The protected dipeptide ester is subsequently subjected to tert-butyl ester cleavage with formic acid (95% v/v, 20–25 °C, 6 h) to expose the carboxylic acid required for final API assembly. This three-step telescoped sequence—free-base liberation, amide bond formation, ester deprotection—is regularly executed in multipurpose stainless steel reactors with precise jacket temperature control (ΔT ±2 °C) and permanent nitrogen purge for moisture-sensitive HATU activation.

Regulatory starting material designation under ICH Q11 Section 5 has been accepted in multiple Drug Master Files when the oxalate is introduced at the step immediately preceding the dipeptide formation and the supplier provides detailed batch genealogy including crystallisation solvent origin and palladium content certificate (Pd ≤10 ppm by ICP-MS, USP <233>). GMP production demands rigorous control of the oxalate particle size distribution (d₉₀ ≤250 µm, laser diffraction, ISO 13320:2020), as rapid dissolution kinetics directly affect phase-split cycle time and residual potassium in the organic stream. End-user manufacturers usually specify a water content limit of ≤0.3% in the oxalate to prevent HATU decomposition during activation; off-specification lots are rectified by vacuum tray drying at 35 °C/10 mbar for 24 h. Isolated yield of the P2-P3 dipeptide tert-butyl ester across the three telescoped steps in production-scale batches (80–120 kg input oxalate) is typically 78–84%; the primary yield loss is attributed to mechanical entrainment in the aqueous potassium carbonate split and formic acid-mediated partial retro-amide cleavage if quench times exceed 45 min. Table 2 presents the typical in-process control limits for the P2 fragment before deprotection.

The final isolated P2 acid, obtained after formic acid concentration and methylcyclohexane antisolvent crystallisation, is a key quality gate: residual tert-butyl ester oxalate originating from incomplete conversion is at this point controlled below 0.10% by HPLC to avoid carrying forward an uncharged intermediate into the final API crystallisation. Multi-tonne production facilities employ wiped-film evaporators for formic acid removal because prolonged batch concentration at >35 °C has been correlated with diketopiperazine formation. The oxalate supplier’s ability to furnish comprehensive extractables-and-leachables statements for packaging materials (conforming to USP <1663>) is increasingly a prerequisite for inclusion in the approved vendor list.

Process chemists investigating scalable routes to peptide epitope mimics often favour direct utilisation of the tert-butyl ester oxalate over the corresponding free amino acid hydrate when the target molecule requires a conformationally locked N-terminal cap. The oxalate is preferably suspended in dichloromethane and treated with 2.2 equivalents of N,N-diisopropylethylamine to quantitatively liberate the free bicyclic amine, which remains predominantly in the organic phase. After filtration of the precipitated N,N-diisopropylethylammonium hydrogenoxalate, the dichloromethane solution is concentrated, and the residue is coupled directly to the activated C-terminus of a side-chain-protected peptide strand. Mixed anhydride activation with isobutyl chloroformate (1.05 eq) and N-methylmorpholine (1.1 eq) in THF at -15 °C has been applied for solution-phase assembly of hexapeptide analogues at 10–50 mmol scale; the hindered secondary amine of the bicyclic ester requires an extended activation period of 45–60 min before peptide coupling is initiated. Failure to extend activation results in mixed anhydride self-disproportionation and lowers coupling yield to ≤40%. For more sterically demanding peptide acids, the PyBOP/DIPEA system (1.15 eq PyBOP, 3.5 eq DIPEA) in DMF at 0 °C to room temperature is preferred; monitored by LC-MS, complete consumption of the peptide acid typically occurs within 6–8 h. The crude N-alkylated peptide tert-butyl ester is purified by preparative C18 HPLC (acetonitrile/water 0.1% TFA linear gradient 30–90% over 30 min, 100 Å pore size, 10 µm particles). Lyophilisation of the pooled fractions furnishes a white fluffy solid with HPLC purity ≥97% and residual TFA content 0.5–2.0% as determined by ion chromatography. The tert-butyl protecting group is intentionally retained throughout the synthesis to serve as a hydrophobicity tag for RP-HPLC separation; it is cleaved only during global deprotection with 95% TFA/2.5% TIS/2.5% water to liberate the terminal carboxylic acid for bioconjugation or solubility optimization. Published data for this specific bicyclic cap in a manufacturing setting are limited, but bench-scale observations indicate that residual oxalate contamination below 0.2% does not interfere with trifluoroacetic acid lysis steps; above this threshold, oxalic acid-mediated decomposition of acid-labile side-chain protecting groups (tBu, Trt) becomes detectable as +1–+3% des-peptide impurities by LC-MS.

If the Tert-Butyl Ester Is Preserved in the Final Ligand Architecture, Can Enantioselectivity Be Predicted?

The rigid [3.3.0] bicyclic framework with bridgehead nitrogen makes the octahydrocyclopenta[c]pyrrole scaffold a versatile chiral controller for organocatalysis and ligand design, provided the tert-butyl ester is either retained as a steric shield or hydrolysed to the carboxylic acid for metal coordination. Exploration of this scaffold in enantioselective Diels–Alder cycloaddition employed the oxalate-derived free amine ester condensed with 2,4-dinitrobenzenesulfonyl chloride to produce a sulfonamide catalyst; the tert-butyl ester group projected inside the chiral pocket was found to increase the endo:exo ratio from 5:1 to 13:1 relative to the methyl ester congener when using cyclopentadiene and cinnamaldehyde in acetonitrile/water at 25 °C (enantiomeric excess 78%). While comprehensive screening data remain primarily in the academic domain, the scalability of the oxalate intermediate allows catalyst libraries to be generated in parallel starting from a single, highly crystalline precursor. Typical ligand elaboration involves liberation of the free base with aqueous 5% NaHCO₃, condensation with a P(III) chloridite reagent to form a phosphoramidite ligand, and immediate use in rhodium-catalysed asymmetric hydrogenation without purification due to the air-sensitivity of the phosphite ester. For such transformations, the oxalate must be free of any transition-metal contaminants: iron content by ICP-OES is set at ≤5 ppm and chloride at ≤50 ppm to avoid competing hydrodehalogenation pathways. The phosphoramidite ligands derived from this scaffold have been examined in hydrogenation of α-acylamidocinnamates; the highest reported enantioselectivity ( 94% ee) was achieved with the tert-butyl ester retained on the periphery, suggesting steric buttressing by the ester group is non-innocent. Published data for this specific configuration are limited, and catalyst performance is highly sensitive to residual moisture and trace oxalate anions that can poison the rhodium centre; accordingly, post-synthesis amination of the oxalate monomer prior to complexation typically includes an additional trituration step with sodium-dried heptane to reduce the water content below 50 ppm. The terminal product is a homogeneous catalyst precursor that is used in sub-1 mol% loadings for pharmaceutical intermediate hydrogenation steps under 10–40 bar hydrogen in stainless steel reactors with gas-induction agitation. No dedicated regulatory monograph governs such ligands, but the oxalate starting material’s residual solvent profile is often cross-referenced against USP <467> limits to ensure the final catalyst does not introduce new impurities into the API at the <10 ppm level.

Certified reference standard programs for viral protease inhibitor active pharmaceutical ingredients routinely require the oxalate salt of the tert-butyl ester as a fully characterised process-related impurity and degradation marker. The compound is isolated from mother liquors of telaprevir intermediate crystallisations or purpose-synthesised and purified by successive recrystallisation from acetonitrile/diethyl ether (1:2 v/v) until HPLC purity exceeds 99.5%. Identity confirmation incorporates high-resolution mass spectrometry (Q-TOF, ESI positive mode, theoretical [M+H]⁺ m/z 240.1594 for the free base), ¹H and ¹³C NMR according to USP <761>, and Fourier-transform infrared spectroscopy. The reference standard is dispensed under ISO 17034:2016 accreditation into amber borosilicate vials with PTFE-lined caps, sealed under argon, and shipped with ice packs when ambient temperature exceeds 25 °C. Assigned purity by mass balance (qNMR minus organic impurities minus water minus residual solvents minus inorganic ash) is reported with an expanded uncertainty (k=2) of ±0.5%. Storage at -20 °C is recommended; periodic requalification by HPLC every 12 months detects any de-esterification or oxidation. End users utilise the standard as an external calibrant for quantitation of residual P2 fragment tert-butyl ester in API batches, with a limit of quantitation of 0.05% relative to the drug substance concentration. The terminal product is a 25 mg or 100 mg certified reference material accompanied by SDS, certificate of analysis, and ISO certificate.

The Bicyclic Ester Requires Additional Purification Prior to DNA Conjugation to Avoid Premature Tag Cleavage

DNA-encoded library (DEL) technology imposes exceptionally stringent purity demands on amine-bearing building blocks to prevent crosslinking, DNA strand scission, or spurious magnesium-complexed aggregates during encoding cycles. The oxalate salt in its commercial form (≥98% HPLC purity) frequently contains trace amounts of free oxalic acid (0.1–0.5% w/w) that, in solution, dissociate sufficient oxalate dianion to sequester Mg²⁺ ions essential for enzymatic ligation of DNA barcodes. A pre-treatment protocol has been established at several DEL synthesis core facilities: the oxalate is partitioned between ethyl acetate and pH 7.0 potassium phosphate buffer (100 mM), the organic phase is filtered through a short plug of anhydrous sodium sulfate, and the solvent is evaporated on a rotary evaporator (≤30 °C bath). The resulting free base tert-butyl ester is re-dissolved in anhydrous N,N-dimethylacetamide and coupled to a headpiece-modified DNA conjugate on a 10 µmol scale using 200 equivalents of the bicyclic amine, HATU (180 eq), and HOAt (180 eq) in the presence of N-ethylmorpholine (400 eq). The coupling mixture is incubated at 30 °C for 16 h with gentle vortexing; LC-MS analysis of the small-molecule fraction after precipitation indicates >90% conversion of the DNA-headpiece based on loss of the starting single-strand peak. Residual amine is removed by ethanol precipitation and size-exclusion chromatography. The terminal product is a DNA-attached bicyclic amino ester that serves as a scaffold for iterative amide bond formation with diverse carboxylic acids in DEL split-and-pool synthesis. No pharmacopoeia or ICH guideline specifically addresses DEL starting materials, but facility standard operating procedures mandate bioburden control (≤10 CFU/mL) and endotoxin level below 0.25 EU/mL for the oxalate before purification to maintain enzymatic activity of Klenow fragment polymerases used in subsequent tagging. The need for pre-purification is a recognised operational bottleneck that limits scale-up of certain DEL selections; direct use of the oxalate without phosphate buffer wash leads to complete loss of ligation efficiency in 3 out of 5 test cycles due to magnesium starvation.